Literature DB >> 10812249

TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.

A M Wilbanks1, S Mahajan, D A Frank, B J Druker, D G Gilliland, M Carroll.   

Abstract

OBJECTIVE: TEL/PDGFbetaR is a tyrosine kinase fusion protein associated with the pathogenesis of chronic myelomonocytic leukemia. The following experiments were undertaken to understand the mechanisms whereby TEL/PDGFbetaR transforms cells.
MATERIALS AND METHODS: Activation of JAK and STAT proteins was studied in an interleukin 3 (IL-3)-dependent cell line, Ba/F3, transformed to IL-3 independence by TEL/PDGFbetaR.
RESULTS: TEL/PDGFbetaR activates STAT1 and STAT5 in transformed Ba/F3 cells through a JAK-independent pathway. Activation of STAT proteins requires the kinase activity of TEL/PDGFbetaR. JAK1, JAK2, JAK3, and TYK2 are not phosphorylated by TEL/PDGFbetaR. However, TEL/PDGFbetaR can phosphorylate STAT5 in transiently transfected COS cells, suggesting that TEL/PDGFbetaR may itself be the kinase involved in tyrosine phosphorylation of STAT proteins. In contrast, native PDGFbetaR stimulated by PDGF ligand does not activate STAT proteins to a significant degree in this hematopoietic context. STAT1 and STAT5 also are activated by TEL/ABL and TEL/JAK2 fusion proteins associated with human leukemia.
CONCLUSIONS: STAT activation may be a common mechanism of transformation by leukemogenic tyrosine kinase fusion proteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812249     DOI: 10.1016/s0301-472x(00)00138-7

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  11 in total

1.  Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

Authors:  Jennifer A Cain; Zhifu Xiang; Julie O'Neal; Friederike Kreisel; AnnaLynn Colson; Hui Luo; Lothar Hennighausen; Michael H Tomasson
Journal:  Blood       Date:  2007-01-11       Impact factor: 22.113

2.  Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.

Authors:  J Frantsve; J Schwaller; D W Sternberg; J Kutok; D G Gilliland
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

3.  Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.

Authors:  Sandrine Medves; Laura A Noël; Carmen P Montano-Almendras; Roxana I Albu; Hélène Schoemans; Stefan N Constantinescu; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

4.  The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.

Authors:  Federica Toffalini; Anders Kallin; Peter Vandenberghe; Pascal Pierre; Lucienne Michaux; Jan Cools; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

5.  Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Authors:  Winnie F Tam; Ting-Lei Gu; Jing Chen; Benjamin H Lee; Lars Bullinger; Stefan Fröhling; Andrew Wang; Stefano Monti; Todd R Golub; D Gary Gilliland
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

Review 6.  STAT signaling in the pathogenesis and treatment of myeloid malignancies.

Authors:  Michal Bar-Natan; Erik A Nelson; Michael Xiang; David A Frank
Journal:  JAKSTAT       Date:  2012-04-01

7.  Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.

Authors:  Hani Kim; Lisa C Gillis; Jordan D Jarvis; Stuart Yang; Kai Huang; Sandy Der; Dwayne L Barber
Journal:  BMC Cancer       Date:  2011-12-28       Impact factor: 4.430

Review 8.  Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.

Authors:  Sandrine Medves; Jean-Baptiste Demoulin
Journal:  J Cell Mol Med       Date:  2012-02       Impact factor: 5.310

9.  Constitutive activation of oncogenic PDGFRα-mutant proteins occurring in GIST patients induces receptor mislocalisation and alters PDGFRα signalling characteristics.

Authors:  Christelle Bahlawane; René Eulenfeld; Monique Y Wiesinger; Jiali Wang; Arnaud Muller; Andreas Girod; Petr V Nazarov; Kathrin Felsch; Laurent Vallar; Thomas Sauter; Venkata P Satagopam; Serge Haan
Journal:  Cell Commun Signal       Date:  2015-03-31       Impact factor: 5.712

10.  A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).

Authors:  Noriyoshi Iriyama; Hiromichi Takahashi; Hiromu Naruse; Katsuhiro Miura; Yoshihito Uchino; Masaru Nakagawa; Kazuhide Iizuka; Takashi Hamada; Yoshihiro Hatta; Tomohiro Nakayama; Masami Takei
Journal:  Mol Genet Genomic Med       Date:  2019-01-29       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.